Leerink Swann Reiterates its Outperform Rating and canadian generic viagra online Price Target of $27 on Amarin Shares

Print E-mail
By Staff and viagra overnight Wire Reports   
Wednesday, 21 November 2012 14:27
icon_MarketCatalystShares of Amarin Corporation (NASDAQ: AMRN) are seeing a technical break-out after Germany's BASF announced plans to acquire Omega 3 Pronova BioPharma in an all-cash offer for $845MM on Wednesday. Pronova manufactures and healthcare of canada pharmacy sells Lovaza to GSK (NYSE: GSK) at a predefined wholesale costs for the ordering viagra US market.
Shares of the 10mg cialis stock reacted almost immediately to the order cheap cialis pre-market news and headed higher after analysts at Leerink Swann said the mexico viagra BASF/Pronova deal "is positive for AMRN since it sets a high floor value for Vascepa, which has superior clinical data and much stronger/longer patent protection so a larger market opportunity exists."

The firm made note of the fact that the cialis next day viagra non prescription BASF takeout transaction was at 3x 2011 sales.

"AMRN's current market cap of roughly $2Bn implies just $667MM peak sales for Vascepa at the same 3x multiple, which we believe is way too low given Lovaza sales reached around 1.3bn last year, with around a tenth of the potential market opportunity," the analyst said.

"One could argue that AMRN deserves a higher multiple as a pharmaceutical product, which would imply an even lower market appreciation for Vascepa peak revenues at present."

The Pronova takeover highlights the viagra sales in canada value for shares of the Dublin Ireland based biopharma and one day delivery cialis Amarin Corporation management has said repeatedly that it prefers a buyout as the path to commercialization of its anti-triglyceride drug Vascepa.


BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
BioMedReports Flexion Therapeutics Announces Clinical Hold Of FX006 Phase 2B Clinical Trial; OXiGENE Initiates Phase 2 Study... http://t.co/DPnZeC0rN1
BioMedReports Researchers discover how bacteria resist antibiotics in hospitals http://t.co/rWKFZF67cR
BioMedReports Healthcare Review: Delcath Systems, ImmunoCellular Therapeutics, Oncolytics Biotech, Concert Pharmaceuticals, ... http://t.co/tcggiO1KtR
Benzinga.com supporter Seeking Alpha Certified